


Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claims 1-9. (Cancelled)

10. (Currently Amended) A method for treating diabetic ~~maculopathy~~macular edema comprising administering to a human subject having diabetic ~~maculopathy with diffuse~~ macular edema an effective amount of a compound represented by the following general formula and ~~ameliorating the diffuse macular edema by the administration:~~



wherein X represents a halogen or a hydrogen atom, and R¹ and R² concurrently or differently represent a hydrogen atom or a C1 to C6 alkyl group,

and ameliorating the diabetic diffuse macular edema by the administration.

11. (Previously Presented) The method for treating diabetic ~~maculopathy~~macular edema according to claim 10, wherein the compound is administered in the form of an oral agent.


12. (Previously Presented) The method for treating diabetic ~~maulopathy~~macular edema according to claim 10, wherein the compound is (2S, 4S)-6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]-2-carboxamide.

13. (Cancelled)

14. (Previously Presented) A method for improving visual acuity and inhibiting a deterioration of visual acuity in a human subject having diabetic maeulopathy~~macular edema~~ comprising the method according to claim 10.

Claims 15-17. (Cancelled)

18. (Currently Amended) A method for treating diabetic ~~maulopathy~~macular edema comprising administering to a human subject having diabetic ~~maulopathy~~ ~~with diffuse macular edema~~ an effective amount of a compound represented by the following general formula, ~~ameliorating the diffuse macular edema by the administration, and consequently inhibiting a deterioration of visual acuity of the subject:~~



wherein X represents a halogen or a hydrogen atom, and R¹ and R² concurrently or differently represent a hydrogen atom or a C1 to C6 alkyl group,

ameliorating the diabetic diffuse macular edema by the administration, and consequently inhibiting a deterioration of visual acuity of the subject.

19. (Cancelled)

20. (Previously Presented) The method for treating diabetic ~~maculopathy~~macular edema according to claim 18, wherein the compound is administered in the form of an oral agent.

21. (Previously Presented) The method for treating diabetic ~~maculopathy~~macular edema according to claim 18, wherein the compound is (2S, 4S)- 6-fluoro-2',5'-dioxospiro [chroman-4,4'-imidazolidine]- 2-carboxamide.